Luxury Beauty Didn't Fail on Science. It Failed Without a Licence.
At L'Oréal, the dermatological division grew 11.3% like-for-like in the first half of 2026 and the luxury division grew 5.4%. The division that grew fastest was neither: professional salon products, at 12.6%. Galderma's quickest segment over the same six months was prescription dermatology, at 67.9%. What is beating luxury beauty is not clinical formulation. It is the licensed professional standing between the product and the buyer.
What do the two European majors actually report?
L'Oréal's half-year accounts put group sales at €23.776 billion, up 6.8% like-for-like. Dermatological Beauty, the division holding CeraVe, La Roche-Posay and SkinCeuticals, reached €4,215.8 million on 11.3% like-for-like growth, 9.3% as reported. L'Oréal Luxe reached €7,996.7 million on 5.4% like-for-like, 4.4% as reported. Luxe remains close to twice the size of the dermatological division and is growing at roughly half the rate.
Galderma's half-year release records net sales of $3.134 billion, up 24.6% at constant currency. Inside that, Injectable Aesthetics grew 12.1%, Dermatological Skincare — the segment holding Cetaphil and Alastin — grew 16.4%, and Therapeutic Dermatology grew 67.9%. Nemluvio, a prescription biologic, contributed $433 million and passed half of Therapeutic Dermatology sales for the first time.
Which of these numbers travels with the wrong label?
Three of them, and the errors all run the same direction. The 24.6% figure is frequently attached to Cetaphil. It belongs to Galderma as a whole: the company's total net sales growth at constant currency. Galderma does not disclose Cetaphil's sales separately at all. The brand sits inside Dermatological Skincare, and 16.4% is the closest verifiable number.
The 9.3% and 4.4% pair for L'Oréal is the reported basis, which includes currency and perimeter effects. The like-for-like pair, 11.3% against 5.4%, is the one that measures underlying demand. Either comparison supports the point that derm is outgrowing luxury by roughly two to one, but mixing a reported figure for one division with a like-for-like figure for another produces a gap that does not exist.
The third is the Estée Lauder skincare decline of 12%, which belongs to the fiscal year ended 30 June 2025, not the current one.
Did luxury skincare actually fall?
It fell, and then it stopped. In fiscal 2025 Estée Lauder's skin care net sales dropped 12% to $6,962 million on both a reported and organic basis, and the filing named declines from the Estée Lauder brand and La Mer alongside weakness in Asia travel retail and mainland China. In fiscal 2026, ended 30 June 2026, skin care rose 5% reported and 4% organic to $7,338 million, and the same filing now names La Mer as a contributor to growth rather than a drag on it.
So the sharper framing is not that luxury skincare is collapsing. It is that luxury skincare spent a year recovering ground it had already lost, while the dermatological brands kept compounding from a higher base. Both can be true, and the second one is the structural fact.
Why does the fastest division break the clinical thesis?
Because it is not clinical. L'Oréal's Professional Products division, which sells through hair salons, grew 12.6% like-for-like — ahead of Dermatological Beauty's 11.3% and more than double Luxe. A salon colourist is not running a safety assessment or citing a study. What a colourist shares with a dermatologist is a licence, a chair and the authority to tell a customer what to buy.
Galderma's own numbers point the same way from the other end. The segment compounding fastest there is prescription medicine, where the buyer does not choose the product at all. A physician does. Therapeutic Dermatology at 67.9% is not evidence that consumers prefer clinical skincare. It is evidence that the fastest-growing category in this industry currently sits outside consumer choice.
So what is the premium actually attached to?
To a third party with standing. For most of the modern history of prestige beauty, the thing that justified a price was held inside the brand: the heritage, the counter, the packaging, the house. That authority was self-issued and it worked for decades. What is displacing it is authority issued by someone else — a pharmacist who stocks the brand, a dermatologist who names it, a colourist who applies it, a prescriber who writes it.
Read that way, the four L'Oréal divisions sort cleanly. The two growing above 11% both reach the customer through a professional. The two growing below 6% both reach the customer off a shelf. Formulation is not the variable doing the work. Distribution through a licensed intermediary is.
Is GLP-1 the cause, or the story the sellers tell?
The evidence that weight-loss medication is driving aesthetic demand is real and it is almost entirely commissioned by the companies selling the remedy. Galderma's own research, published alongside an international Delphi consensus on managing aesthetic needs in rapid medication-driven weight loss, reports that 62% of GLP-1 users received an aesthetic treatment after a clinician recommended one, and that 48% noticed significant facial changes. A separate survey of 400 clinicians presented at a dermatologic surgery meeting in November 2025 found 81% using hyaluronic acid fillers for GLP-1-related concerns, with the average number of GLP-1 patients per provider rising from 95 in 2023 to 225 in 2024. That survey was run by Allergan Aesthetics, which sells the fillers.
None of this makes the effect imaginary. Both datasets describe the same mechanism from the inside of an industry that profits from it, which is a reason to treat the direction as established and the magnitude as unsettled. The more durable observation underneath the GLP-1 story is simply that a clinician entered the purchase decision, which is the same shift the division numbers show.
Where does Korea sit in this?
On both sides of it, which is unusual. Korean pharmaceutical companies have spent a decade building consumer skincare brands rather than licensing their names to one: Dongkook Pharmaceutical owns Centellian24, Daewoong owns Easydew, Dong-A owns Fation, Dongwha owns Fusidyne and Hanmi Science owns Adesii. Dongkook reported first-quarter 2026 revenue of 251.0 billion won, about $185 million at 1,357 won to the dollar on 1 October 2026, up 12.2%, with Centellian24 exports up 332% against the same quarter a year earlier. Cumulative Centellian24 sales from 2015 to 2024 reached 1 trillion won, roughly $737 million.
Olive Young then did something no Western retailer has an equivalent for: it turned the pharmaceutical origin into a named shelf. Advanced Derma launched in March 2026 as a category co-developed with domestic pharmaceutical companies, reached 650 stores by early August, and recorded June sales more than 260% above April. Around 70% of its buyers are foreign. A category built on Korean clinical credibility is being bought largely by people who do not live in Korea.
Who supplies the clinical boom itself?
Korean manufacturers, to a degree the Western division reports do not show. Hugel recorded first-half 2026 revenue of 254.5 billion won, about $188 million, with botulinum toxin revenue of 149.4 billion won, roughly $110 million, up 46.6%, and toxin sales in the Americas more than doubling. PharmaResearch recorded second-quarter exports of 84 billion won, about $62 million, up 62% and amounting to 47% of its revenue, with cosmetics exports alone up 124%.
So when a European group reports that injectable aesthetics grew 12.1% and attributes part of it to medication-driven weight loss, a share of the volume behind that demand originates in Korean plants. The clinical premium is being captured in Western income statements and manufactured, in part, somewhere else. That is the same structure K-beauty has run in colour and skincare for twenty years, arriving now in a category with a prescription attached.
Where does this leave the three sides?
For manufacturers and ODM partners — the contract developers that design and produce under other companies' brand names — the valuable capability is shifting from speed of launch to evidence a professional will repeat. A formula that a pharmacist can defend is worth more than a formula that trends. For brands and the buyers who source them, the question at a sourcing meeting changes from what the range looks like to who signs off on it, and the answer is a document rather than a mood board. For regulators and investors, the boundary between cosmetics and medicine is where the growth now sits, and it is a boundary with two different rulebooks, two different liability regimes and two different approval clocks on either side of it.
Luxury beauty did not lose to better chemistry. It lost the exclusive right to say what works. The companies growing fastest are the ones that borrowed that right from someone licensed to hold it.
Comments